How a bacterial compound contributes to gum disease inflammation
Microbial methylglyoxal promotes periodontal inflammation
This study is looking at how a substance made by certain bacteria in your mouth can cause gum inflammation and tooth loss, helping patients understand how these infections might affect their oral health.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project ID | NIH-10692690 on NIH RePORTER |
What this research studies
This research investigates the role of a compound called methylglyoxal (MGO), produced by the bacteria Tannerella forsythia, in causing inflammation associated with periodontal disease. The study aims to understand how MGO modifies proteins in the gums, leading to a chronic inflammatory response that can result in tooth loss. By examining the molecular mechanisms of MGO's effects, researchers hope to uncover new insights into the relationship between this bacterium and periodontal health. Patients may learn more about how their oral health is affected by bacterial infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from periodontal disease, particularly those with chronic inflammation and tooth loss.
Not a fit: Patients without periodontal disease or those who do not have the specific bacterial infection being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for periodontal disease that target the inflammatory processes caused by bacterial compounds.
How similar studies have performed: Previous research has shown that targeting bacterial products can lead to improvements in periodontal health, suggesting that this approach may be promising.
Where this research is happening
Amherst, United States
- State University of New York at Buffalo — Amherst, United States (Active)
Researchers
- Principal investigator: Settem, Rajendra Prasad — State University of New York at Buffalo
- Study coordinator: Settem, Rajendra Prasad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.